Diabetes drug class may reduce gout risk

Large study of patients with diabetes demonstrates uric acid reduction

Treatment with an SGLT-2 inhibitor may protect against gout in adults with type 2 diabetes, research suggests.


US researchers drew on a nationwide commercial insurance database to compare a cohort of 119,530 patients newly prescribed an SGLT-2 inhibitor with a similar number newly prescribed a GLP-1 receptor agonist, with mean follow-up of 302 days and 261 days, respectively.

The incidence of gout was significantly lower among patients prescribed an SGLT-2 inhibitor (4.9 vs 7.8 events per 1000 person-years) and the study showed an absolute risk